AR095669A1 - Toxinas, composiciones y métodos relacionados - Google Patents

Toxinas, composiciones y métodos relacionados

Info

Publication number
AR095669A1
AR095669A1 ARP140101275A ARP140101275A AR095669A1 AR 095669 A1 AR095669 A1 AR 095669A1 AR P140101275 A ARP140101275 A AR P140101275A AR P140101275 A ARP140101275 A AR P140101275A AR 095669 A1 AR095669 A1 AR 095669A1
Authority
AR
Argentina
Prior art keywords
methods
toxins
compositions
related methods
inactivation
Prior art date
Application number
ARP140101275A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AR095669A1 publication Critical patent/AR095669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ARP140101275A 2013-03-15 2014-03-18 Toxinas, composiciones y métodos relacionados AR095669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095669A1 true AR095669A1 (es) 2015-11-04

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101275A AR095669A1 (es) 2013-03-15 2014-03-18 Toxinas, composiciones y métodos relacionados

Country Status (13)

Country Link
US (2) US20160045586A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968507A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016516721A (cg-RX-API-DMAC7.html)
KR (1) KR20150133770A (cg-RX-API-DMAC7.html)
CN (1) CN105338997A (cg-RX-API-DMAC7.html)
AR (1) AR095669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014228956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907154A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213800A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507608PA (cg-RX-API-DMAC7.html)
TW (1) TWI624474B (cg-RX-API-DMAC7.html)
WO (1) WO2014144567A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4444742A4 (en) * 2021-12-06 2025-12-10 Univ Rutgers Compositions and Methods for Treating Cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
KR20150133770A (ko) 2015-11-30
EP2968507A2 (en) 2016-01-20
CA2907154A1 (en) 2014-09-18
JP2016516721A (ja) 2016-06-09
SG11201507608PA (en) 2015-10-29
WO2014144567A2 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
WO2014144567A3 (en) 2014-12-04
US20160045586A1 (en) 2016-02-18
BR112015023332A2 (pt) 2017-08-22
HK1213800A1 (zh) 2016-07-15
CN105338997A (zh) 2016-02-17
TWI624474B (zh) 2018-05-21
US20180028637A1 (en) 2018-02-01
AU2014228956A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
SV2018005792A (es) Nuevos derivados piperidinilo sustituidos con hetero (arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20140275A (es) Triazolopiridinas sustituidas
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
DOP2016000069A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20170336A (es) Compuestos de azolina sustituidos con un sistema de anillos condensados
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
NI201600016A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los continen.
MX2016017025A (es) Formulaciones de proteinas.
CL2017001641A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado.
CR20160016A (es) Pirazolpiridinas sustituidas
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
WO2014144567A3 (en) Toxoid, compositions and related methods
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
MX2015016571A (es) Revestimientos de geomembranas a altas temperaturas y composiciones de lote maestro.
AR099132A1 (es) Colorante-polímero

Legal Events

Date Code Title Description
FB Suspension of granting procedure